Core Insights - Several biotechnology and pharmaceutical companies experienced significant gains in after-hours trading due to corporate updates and upcoming event announcements [1] Company Updates - Jasper Therapeutics, Inc. (JSPR) saw a 21.51% increase to $2.09 after hours, following the announcement of a webinar on December 2 to present findings from the BEACON study and preliminary data from the ETESIAN study [2] - NRx Pharmaceuticals, Inc. (NRXP) rose 13.39% to $2.71 after hours, with the CEO scheduled to present at NobleCon21 on December 3, discussing the company's expanded focus and clinical revenue progress [3] - Unicycive Therapeutics, Inc. (UNCY) increased by 5.42% to $6.33, with the CEO participating in two upcoming events, although no new announcements were made on Monday [4] - Spruce Biosciences, Inc. (SPRB) shares rose 4.68% to $87.00 after reporting a net loss of $8.2 million for the quarter ending September 30, 2025, an improvement from a net loss of $8.7 million in the previous year [5] - Evaxion A/S (EVAX) added 3.96% to $5.65, announcing progress in its CMV vaccine program with new protective data and ongoing preclinical development [6] - Solana Company (HSDT) gained 3.48% to $3.87, reporting a net loss of $352.8 million for the third quarter, a significant increase from a net loss of $3.7 million in the prior-year period, with revenue totaling $697,000 [7] - Protara Therapeutics, Inc. (TARA) rose 5.04% to $7.08, planning a conference call on December 3 to review interim data from its Phase 2 trial of TARA-002 in bladder cancer patients [8]

Core Viewpoint - Jasper Therapeutics is hosting a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study, focusing on briquilimab's potential in treating mast cell driven diseases [1][2] Group 1: Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting c-Kit (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [3] - Briquilimab works by blocking stem cell factor from binding to the KIT receptor, leading to mast cell depletion and reducing inflammation associated with these diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, showing positive outcomes in CSU and CIndU [3] Group 2: Webinar Details - The webinar is scheduled for Tuesday, December 2, 2025, at 8:00 am ET, featuring presentations from Jasper management and Dr. Martin Metz, a leading investigator in the BEACON study [1][2] - A live Q&A session will follow the formal presentation, allowing for direct engagement with the audience [1]

Core Insights - Bragar Eagel & Squire, P.C. is investigating officers and directors of Driven Brands Holdings, Inc. and Jasper Therapeutics, Inc. on behalf of long-term stockholders due to class action complaints filed against both companies [1][4] Driven Brands Holdings, Inc. (NASDAQ: DRVN) - A class action complaint was filed against Driven Brands on December 22, 2023, alleging that the company made materially false and misleading statements regarding its ability to integrate acquired businesses and the performance of its car wash segment [2][3] - The complaint claims that Driven Brands misrepresented its integration capabilities as a "core strength" and assured investors of "significant progress" in integrating its U.S. auto glass businesses, while downplaying issues related to customer demand in its car wash segment [3] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - A class action complaint was filed against Jasper Therapeutics on September 19, 2025, alleging that the company made materially false and misleading statements about its business operations and compliance policies [4][5] - The complaint highlights that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which increased risks for ongoing studies and overstated the company's financial and clinical prospects [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Legal Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The alleged failures increased the risk of confounding results in ongoing studies and the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects [5].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with deadlines for filing lead plaintiff motions set for November 18, 2025 [1] Quanex Building Products Corporation (NYSE: NX) - Class period spans from December 12, 2024, to September 5, 2025, with allegations of materially false and misleading statements made by defendants [2] - Key issues include significant underinvestment in tooling and equipment maintenance at the Tyman Mexico facility, leading to degraded conditions and potential significant costs that could delay expected benefits from the Tyman integration [2] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - Class period runs from November 30, 2023, to July 3, 2025, with similar allegations of misleading statements and undisclosed adverse facts [3] - Defendants failed to disclose lack of necessary controls for third-party manufacturers, increasing risks to ongoing studies and overstating the company's business and financial prospects [3] KBR, Inc. (NYSE: KBR) - Class period is from May 6, 2025, to June 19, 2025, with allegations of misleading statements regarding the partnership with TRANSCOM and its ability to fulfill contracts [5] - Defendants claimed no issues with the partnership despite known material concerns, leading to misleading statements about the company's operations and prospects [5]

Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Legal Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting its own success in recovering significant settlements for investors [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The alleged failures increased the risk of confounding results in ongoing studies and overstated the company's business and financial prospects [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with regulations, which negatively impacted the prospects of its products, including briquilimab [5] - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues allegedly increased the risk of confounding study results and the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects [5].

Core Points - Rosen Law Firm is reminding investors of Jasper Therapeutics, Inc. about the November 18, 2025 deadline to join a securities class action lawsuit related to the company's stock purchased between November 30, 2023, and July 3, 2025 [1][2] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 18, 2025 deadline [3] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] Group 2: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations [5] - It is claimed that these failures increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab [5] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true details became known [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which could negatively impact its regulatory and commercial prospects [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. - It is important to note that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].